In principle, NK2R agonists could be leveraged to treat metabolic diseases including obesity, whereas NK2R antagonists may ameliorate mucosal inflammation in inflammatory bowel disease. This evidence concerns the gene TACR2 and obesity due to melanocortin 4 receptor deficiency.